Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide

详细信息    查看全文

• 作者：David Jamieson^a ; Nicola Sunter^a ; Sara Muro^a ; Lucie Pouché ; ^a ; Nicola Cresti^a ; ^b ; Johanne Lee^a ; Julieann Sludden^a ; Melanie J. Griffin^a ; James M. Allan^a ; Mark W. Verrill^a ; ^b ; Alan V. Boddy^c ; ^{alan.boddy@sydney.edu.au}
• 关键词：Cancer chemotherapy drugs ; Cyclophosphamide ; Doxorubicin ; Pharmacogenetics ; MBL2 ; CD95 ; Infection
• 刊名：European Journal of Cancer
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：71
• 期：Complete
• 页码：15-24
• 全文大小：800 K
• 卷排序：71

文摘

MBL2 single nucleotide polymorphism (SNP) associated with Grade 3 infection following cytotoxic chemotherapy. CD95 SNP associated with grade 3 infection following cytotoxic chemotherapy. CD95 SNP associated with mild neutrophilia and increased white blood cell count. Potential to identify patients likely to benefit from prophylactic colony stimulating factor therapy.